TITAN PHARMACEUTICALS INC
S-3, EX-5.1, 2001-01-11
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: TITAN PHARMACEUTICALS INC, S-3, 2001-01-11
Next: TITAN PHARMACEUTICALS INC, S-3, EX-23.1, 2001-01-11



<PAGE>

                                                                     EXHIBIT 5.1
Direct Dial: 212-407-4935
e-mail: [email protected]


                                January 11, 2001

Titan Pharmaceuticals, Inc.
400 Oyster Point Boulevard
South San Francisco, CA


                Re:      Registration Statement on Form S-3
                         ----------------------------------
Gentlemen:

         We have acted as counsel to Titan Pharmaceuticals, Inc., a Delaware
corporation (the "Company"), in connection with the preparation of a
registration statement on Form S-3 (the "Registration Statement") filed with the
Securities and Exchange Commission under the Securities Act of 1933, as amended
(the "Act"), relating to the registration of an aggregate of 93,590 shares (the
"Shares") of the common stock, par value $.001 per share, of the Company (the
"Common Stock") for resale by certain selling stockholders named therein (the
"Selling Stockholders").

         In this connection, we have reviewed (a) the Registration Statement;
(b) the Company's Restated Certificate of Incorporation and Bylaws; (c) the
agreement and plan of merger between the Company and GeoMed, Inc. dated July 11,
2000; (d) certain records of the Company's corporate proceedings as reflected in
its minute books. In our examination, we have assumed the genuineness of all
signatures, the authenticity of all documents submitted to us as originals and
the conformity with the original of all documents submitted to us as copies
thereof. Where factual matters relevant to such opinion were not independently
established, we have relied upon certificates of officers and responsible
employees and agents of the Company. Our opinion set forth below is limited to
the General Corporation Law of the State of Delaware.

         Based upon the foregoing, it is our opinion that the Shares have been
duly and validly authorized and issued and are fully paid and nonassessable.

         We hereby consent to the use of this opinion as Exhibit 5.1 to the
Registration Statement and to all references to our firm in the Registration
Statement. In giving this consent, we do not thereby concede that we come within
the categories of persons whose consent is required by the Act or the General
Rules and Regulations promulgated thereunder.

                                            Very truly yours,

                                            /s/ LOEB & LOEB LLP

                                            LOEB & LOEB LLP



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission